New tricks

Article

Breaking news from Day 3 of ESCRS

Breakthrough micro-lens treatment for presbyopia
The Flexivue System, a breakthrough implantable micro-lens treatment for presbyopia from Presbia Coöperatief was unveiled at the show and it is keenly anticipated that it will be in clinical trials in several European countries by the end of the year.

Alcon to acquire Swiss Biotechnology business
The news broke at today's show that Alcon is to gain access to proprietary antibody fragment technology particularly suited to treat eye diseases with its plan to acquire ESBATech AG, a Swiss biotechnology firm.

Toric IOL enhances refractive outcomes
Rayner, the world's first IOL manufacturer, unveiled a dynamic new brand identity at ESCRS and held a seminar today to highlight the success doctors are having with its range of toric IOLs. Headlined A Roadmap to Success the seminar featured presentations from seven European doctors relating their experiences of using Rayner's toric IOLs.

More news from the congressImproving retinal examination speed and efficiency Megatron S4 from Geuder delivers flexibility and mobilityThree steps to better toric surgeryA quartet of solutions for surgeonsAt the sharp endAn all in one optical biometer

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.